Background
==========

Obesity, especially excess accumulation of visceral fat, is upstream of obesity-related disorders including atherosclerotic cardiovascular disease \[[@B1]\]. Visceral fat accumulation represents positive energy balance, conditioned by genetic and environmental factors, such as high-fat and/or high sucrose diet, physical inactivity, sleep-disorders, and mental stress \[[@B1]\]. Polyunsaturated fatty acids have an important role in human diet, both in the prevention and treatment of pathologies \[[@B2],[@B3]\]. Previous studies reported that an imbalance of dietary long-chain polyunsaturated fatty acids, especially low omega-3/omega-6 polyunsaturated fatty acids ratio, is associated with increased risk of cardiovascular disease \[[@B4]-[@B6]\]. To our knowledge, the relationship between visceral fat volume and omega-3/omega-6 polyunsaturated fatty acid ratio has not yet been characterized. The present study investigated the correlation between omega-3 polyunsaturated fatty acid (eicosapentaenoic acid \[EPA\], docosahexaenoic acid \[DHA\]), omega-6 polyunsaturated fatty acid (arachidonic acid \[AA\], and clinical features in male subjects.

Methods and procedures
======================

Study population
----------------

The study subjects were 134 consecutive Japanese subjects with diabetes, hypertension and/or dyslipidemia, who visited the outpatient clinic of "Diabetes & Metabolic Station" at Osaka University Hospital, between September 2009 and August 2012. The Medical Ethics Committee of Osaka University approved this study. All participants were Japanese and each gave a written informed consent. This study (ADMIT study) is registered under number UMIN000002271.

Definition of coronary artery diseases
--------------------------------------

Documented coronary artery diseases (CAD) encompassed one or more of the following: history of stable with documented CAD evaluated with stress electrocardiography, such as ergometry or double master's two-step test, multi-detector row computed tomography or coronary angiography; history of previous acute coronary syndrome including unstable angina and myocardial infarction evaluated with coronary angiography and underwent percutaneous coronary intervention or coronary artery bypass graft surgery.

Anthropometric data and laboratory tests
----------------------------------------

Anthropometric variables \[height, weight and waist circumference (WC)\] were measured in the standing position. WC at the umbilical level was measured with a non-stretchable tape in late expiration while standing (in cm). Body mass index (BMI) was calculated using the formula \[*weight*(*kg*)/*height*(*m*)^2^\]. Visceral fat area was estimated by the bioelectrical impedance analysis method (eVFA), as reported previously by our group \[[@B7]\]. Briefly, the voltage recorded at the flank to the flow of current between the umbilicus and the back correlates significantly with visceral fat area and is not influenced by the amount of subcutaneous fat. We demonstrated previously that eVFA correlates significantly with that determined by computed tomography \[[@B7]\]; the coefficient of variation of the bioelectrical impedance analysis method with the computed tomography value was 0.89% in the standing posture and late expiration.

Blood pressure was measured with a standard mercury sphygmomanometer on the right arm in the supine position after at least 10-minute rest. After overnight fasting state, venous blood samples were collected for measurements of blood glucose, hemoglobin A1c (HbA1c) \[National Glycohemoglobin Standardization Program (NGSP)\], triglyceride, and high-density lipoprotein-cholesterol (HDL-C), uric acid, and creatinine. Low-density lipoprotein-cholesterol (LDL-C) was calculated with the Friedewald equation. Urine albumin-creatinine ratio (UACR) was calculated from a single spot urine specimen collected between morning and afternoon.Urine albumin concentration was determined by the immunoturbidimetric method (N-assay TIA MicroAlb, Nittobo Medical, Japan). Estimated GFR (eGFR) was calculated using the simplified Modification of Diet in Renal Disease equation modified by the appropriate coefficient for Japanese populations by gender, as described previously \[[@B8]\]. The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated using the following formula: *HOMA* − *IR* (*milliunits per liter* × *milligrams per deciliter*) = \[(*fasting IRI*(*microunit*/*mL*) × *fasting glucose* \[*mg*/*mL*\])/405\]. Measurement of serum EPA, DHA and AA levels was outsourced to SRL (Tokyo, Japan). In brief, plasma lipids were extracted by Folch's procedure, and then fatty acids (tricosanoicacid, C23:0, as the internal standard) were methylated with boron trifluoride and methanol. The methylated fatty acids were then analyzed using a capillary gas chromatograph (GC-2010; Shimadzu, Kyoto, Japan).

Subjects were divided according to smoking habit into current or ex-smokers and non-smokers. Diabetes mellitus was defined according to World Health Organization criteria or regular treatment with anti-diabetic agents. Dyslipidemia was defined as total cholesterol concentration of ≥220 mg/dL, triglyceride concentration ≥150 mg/dL, HDL-C concentration \<40 mg/dL, or regular treatment with anti-lipidemic agents. Hypertension was defined as systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or regular treatment with anti-hypertensive agents. Patients with a previous diagnosis of dyslipidemia, hypertension, or diabetes mellitus and receiving drugs for any of these conditions were also included in this study. The metabolic syndrome was diagnosed according to the Japanese criteria for the metabolic syndrome \[[@B9]\].

Statistical analysis
--------------------

All values were expressed as mean±SD. Data of eVFA, and triglyceride levels showed skewed distribution, and were therefore log-transformed before analysis. Relationships between two continuous variables were analyzed using scatter plots and Pearson's correlation coefficients. Data of the two groups were compared by the Student's *t*-test or the Mann--Whitney test. The frequencies were compared between two groups by the χ2 test. The correlations between EPA,DHA, AA, EPA/AA, DHA/AA, (EPA+DHA)/AA and other parameters were first analyzed by simple regression analysis and then by multivariate stepwise analysis. In all cases, *p* values \<0.05 were considered statistically significant. All analyses were performed with the JMP Statistical Discovery Software 8.0 (SAS Institute, Cary, NC).

Results
=======

Subjects' characteristics
-------------------------

Table [1](#T1){ref-type="table"} summarizes the characteristics of all male subjects enrolled in this study. Visceral fat accumulation (eVFA ≥100 cm^2^) based on Japanese criteria of visceral fat accumulation \[[@B10]\] was identified in 76.9% (n=103/134). Figure [1](#F1){ref-type="fig"} showed the distribution of EPA, DHA, AA, EPA/AA, DHA/AA and (EPA+DHA)AA ratios.

###### 

Baseline characteristics

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------
  n (Male)                                                                                                                                                                                 134
  Age, years                                                                                                                                                                               64±12 (25--86)
  Body mass index (BMI), kg/m^2^                                                                                                                                                           25.6±3.9 (18.1-38.5)
  Waist circumference (WC), cm                                                                                                                                                             90.6±10.7 (68--130)
  Estimated visceral fat area (eVFA), cm^2^                                                                                                                                                142±60 (36--371)
  History of smoking (%)                                                                                                                                                                   82.1
  Brinkman index                                                                                                                                                                           747±666 (0--3520)
  Hypertension (%)                                                                                                                                                                         66.4
  (calcium channel antagonist / angiotensin converting enzyme inhibitor or angiotensin receptor blocker / eplerenone / aliskiren fumarate / beta blockade / diuretics / alpha blockade )   (n=49/60/1/1/13/15/2)
  Systolic blood pressure (SBP), mmHg                                                                                                                                                      132±16 (94--180)
  Diastolic blood pressure (DBP), mmHg                                                                                                                                                     76±11 (52--111)
  Diabetes (%)                                                                                                                                                                             78.4
  (sulfonyl ureas / glinides / biguanides / pioglitazone /alpha glucosidase inhibitors / dipeptidyl peptidase-IV inhibitors / glucagon-like peptide-1 agonists / Insulin)                  (n=42/3/25/24/21/11/1/20)
  Fasting blood glucose (FBG), mg/dL                                                                                                                                                       128±35 (56--261)
  Hemoglobin A1c (HbA1c), (NGSP),%                                                                                                                                                         6.9±1.1 (4.9-10.7)
  HOMA-IR, units                                                                                                                                                                           3.1±2.4 (0.47-14.1)
  Estimated glomerular filtration rate (eGFR), mL/min                                                                                                                                      69.5±17.7 (24.4-110.6)
  Urine albumin-creatinine ratio (UACR), mg/g creatinine                                                                                                                                   175.1±552.0 (0.5-3958)
  Dyslipidemia (%)                                                                                                                                                                         67.9
  (statins / fibrates / ezetimibe / cholestimide / probucol)                                                                                                                               (n=59/3/5/1/2)
  Total cholesterol (T-cho), mg/dL                                                                                                                                                         192±37 (112--335)
  Low-density lipoprotein-cholesterol (LDL-C), mg/dL                                                                                                                                       112±33 (55--259)
  Triglyceride (TG), mg/dL                                                                                                                                                                 142±91 (32--681)
  High-density lipoprotein-cholesterol (HDL-C), mg/dL                                                                                                                                      53±16 (23--157)
  Metabolic syndrome (%)                                                                                                                                                                   55.2
  Eicosapentaenoic acid (EPA), μg/mL                                                                                                                                                       63.8±35.7 (11.1-212.4)
  Docosahexaenoic acid (DHA) , μg/mL                                                                                                                                                       140.0±67.3 (41--610.3)
  Arachidonic acid (AA), μg/mL                                                                                                                                                             172.1±53.5 (72.5-413.4)
  EPA/AA ratio                                                                                                                                                                             0.39±0.24 (0.09-1.41)
  DHA/AA ratio                                                                                                                                                                             0.83±0.32 (0.35-1.98)
  (EPA+DHA)/AA ratio                                                                                                                                                                       1.23±0.52 (0.45-3.27)
  History of coronary artery diseases (CAD) (%)                                                                                                                                            39.6
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------

Data are mean ± SEM (range), or number of subjects. HOMA-IR, homeostasis model assessment of insulin resistance.

![Distribution of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), arachidonic acid (AA), EPA/AA ratio, DHA/AA ratio, (EPA+DHA)/AA ratio.](1743-7075-10-25-1){#F1}

Correlation between serum levels of EPA, DHA, AA, EPA/AA DHA/AA, (EPA+DHA)AA ratios and clinical features
---------------------------------------------------------------------------------------------------------

Table [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"} summarize the results of correlation analyses of serum levels of EPA, DHA, AA, EPA/AA, DHA/AA, (EPA+DHA)/AA ratios with various clinical parameters. EPA correlated significantly and positively with LDL-C, HDL-C, DHA, and AA. Stepwise regression analysis that included LDL-C, HDL-C, DHA, and AA identified HDL-C, DHA, and AA correlated significantly and independently with EPA. DHA correlated significantly and positively with LDL-C, log-TG, EPA, and AA. Stepwise regression analysis that included LDL-C, log-TG, EPA, and AA identified log-TG, EPA, and AA correlated significantly and independently with DHA. AA correlated significantly and negatively with age, and positively with BMI, WC, eVFA, HOMA-IR, eGFR, LDL-C, log-TG, EPA, and DHA. Stepwise regression analysis that included age, BMI, eVFA, HOMA-IR, eGFR, LDL-C, log-TG, EPA, and DHA, demonstrated that age and DHA correlated significantly and independently with AA.

###### 

Correlations between serum EPA, DHA, AA, and various parameters

                   **Serum EPA**   **Serum DHA**   **Serum AA**                                                   
  ---------------- --------------- --------------- -------------- -------- --------- --------- -------- --------- ---------
  Age              0.066           0.449                          −0.019     0.829             −0.381   \<0.001   0.002
  BMI              −0.049          0.577                          0.064      0.465             0.216    0.012     0.952
  WC               −0.083          0.342                          0.042      0.632             0.172    0.048     \-
  Log-eVFA         −0.108          0.218                          0.058      0.506             0.203    0.020     0.242
  Brinkman index   −0.111          0.207                          −0.139     0.114             −0.091   0.300      
  SBP              0.049           0.571                          0.101      0.244             −0.029   0.739      
  DBP              −0.016          0.857                          0.058      0.503             0.022    0.801      
  FBG              −0.029          0.745                          −0.013     0.886             0.024    0.786      
  HbA1c            −0.059          0.510                          −0.072     0.416             −0.059   0.503      
  HOMA-IR          0.063           0.547                          0.136      0.193             0.228    0.028     0.909
  eGFR             0.045           0.608                          −0.030     0.732             0.160    0.038     0.353
  UACR             0.155           0.126                          0.150      0.138             0.076    0.455      
  LDL-C            0.233           0.008           0.142          0.256      0.004   0.424     0.236    0.007     0.835
  HDL-C            0.181           0.037           0.030          0.113      0.196             0.122    0.161      
  Log-TG           0.087           0.320                          0.371     \<0.001  \<0.001   0.403    \<0.001   0.390
  EPA                                                             0.757     \<0.001  \<0.001   0.251    0.004     0.259
  DHA              0.757           \<0.001         \<0.001                                     0.517    \<0.001   \<0.001
  AA               0.251           0.004           0.001          0.517     \<0.001  \<0.001                       

Data are mean ± SEM (range), or number of subjects. Abbreviations as in Table [1](#T1){ref-type="table"}. Parameters with p\<0.05 in univariate analysis were subsequently entered into stepwise regression analysis as significant and independent variables. EPA (adopted parameters; LDL-C, HDL-C, DHA, AA), DHA (adopted parameters; LDL-C, Log-TG, EPA, AA), AA (adopted parameters; age, BMI, Log-eVFA, HOMA-IR, eGFR, LDL-C, log-TG, EPA, DHA).

###### 

Correlations between serum EPA/AA, DHA/AA, (EPA+DHA)/AA ratios and various parameters

                   **Serum EPA/AA ratio**   **Serum DHA/AA ratio**   **Serum (EPA+DHA)/AA ratio**                             
  ---------------- ------------------------ ------------------------ ------------------------------ -------- ------- -------- ---------
  Age              0.242                    0.005                    0.003                          0.296    0.001   0.295    \<0.001
  BMI              −0.162                   0.061                                                   −0.127   0.144   −0.154   0.076
  WC               −0.176                   0.042                    \-                             −0.117   0.179   −0.153   0.077
  Log-eVFA         −0.212                   0.015                    0.026                          −0.097   0.269   −0.157   0.071
  Brinkman index   −0.081                   0.696                                                   −0.081   0.359   −0.066   0.453
  SBP              0.079                    0.679                                                   0.135    0.120   0.100    0.251
  DBP              −0.076                   0.631                                                   0.056    0.521   0.015    0.867
  FBG              −0.009                   0.919                                                   −0.016   0.856   −0.016   0.851
  HbA1c            −0.010                   0.915                                                   −0.015   0.863   −0.013   0.879
  HOMA-IR          −0.064                   0.543                                                   −0.032   0.763   −0.047   0.654
  eGFR             0.045                    0.614                                                   −0.079   0.373   −0.029   0.740
  UACR             0.043                    0.674                                                   0.035    0.729   0.041    0.684
  LDL-C            0.063                    0.481                                                   0.058    0.514   0.065    0.463
  HDL-C            0.098                    0.264                                                   0.45     0.611   0.072    0.409
  Log-TG           −0.154                   0.076                                                   0.074    0.396   −0.026   0.767

Data are mean ± SEM (range), or number of subjects. Abbreviations as in Table [1](#T1){ref-type="table"}. Parameters with p\<0.05 in univariate analysis were subsequently entered into stepwise regression analysis as significant and independent variables. EPA/AA (adopted parameters; age, eVFA).

The EPA/AA ratio correlated significantly and positively with age, and negatively WC and eVFA. Stepwise regression analysis demonstrated that age and eVFA correlated significantly and independently with EPA/AA ratio. The DHA/AA ratios and (EPA+DHA)/AA ratios correlated significantly and positively with age only.

Serum AA levels correlated positively with eVFA and serum EPA/AA and (EPA+DHA)/AA levels correlated negatively with eVFA, however, there was no significant correlation between EPA, DHA, DHA/AA ratio, and eVFA (Figure [2](#F2){ref-type="fig"}).

![**Correlations between EPA, DHA, AA, EPA/AA ratio, DHA/AA ratio, (EPA+DHA)/AA ratio, and estimated visceral fat area (eVFA).** Pearson's correlation coefficient was used to examine the relationship between EPA, DHA, AA, EPA/AA ratio, DHA/AA ratio, (EPA+DHA)+AA ratios, and eVFA. Abbreviations as in Figure [1](#F1){ref-type="fig"}.](1743-7075-10-25-2){#F2}

Comparisons of clinical features in subjects with eVFA \<100 cm^2^ and ≥100 cm^2^
---------------------------------------------------------------------------------

Table [4](#T4){ref-type="table"} shows the characteristics of subjects with eVFA \<100 cm^2^ and ≥100 cm^2^ based on Japanese criteria of visceral fat accumulation \[[@B9]\]. The proportion of patients with hypertension, and the levels of HOMA-IR and serum triglyceride were significantly higher in the eVFA ≥100 cm^2^ group, compared to the eVFA \<100 cm^2^ group. Serum HDL-C levels were significantly lower in subjects with eVFA ≥100 cm^2^, than those with eVFA \<100 cm^2^. Differences in serum EPA, DHA, and AA levels were not significant between the two groups (Figure [3](#F3){ref-type="fig"}A-C). Serum EPA/AA ratio, but not serum DHA/AA and (EPA+DHA)/AA ratios, was significantly lower in the eVFA ≥100 cm^2^ group, compared to the eVFA \<100 cm^2^ group (Figure [3](#F3){ref-type="fig"}D-F). A larger proportion of subjects with eVFA ≥100 cm^2^ were diagnosed with the metabolic syndrome and cardiovascular diseases, compared to those with eVFA \<100 cm^2^ (Figure [4](#F4){ref-type="fig"}A,B).

###### 

**Comparison of various parameters between subjects with eVFA \<100 cm**^**2**^**and eVFA ≥100 cm**^**2**^

                           **eVFA \<100 cm**^**2**^**group**   **eVFA ≥100 cm**^**2**^**group**   **p value**
  ------------------------ ----------------------------------- ---------------------------------- -------------
  n (Male)                 31                                  103                                 
  Age, years               62±16 (25--86)                      65±11 (27--85)                     0.239
  BMI, kg/m^2^             21.7±1.9 (18.1-25.8)                26.7±3.6 (20.6-38.5)               \<0.001
  WC, cm                   78.0±4.6 (68--90)                   94.4±9.0 (78--130)                 \<0.001
  History of smoking (%)   67.7                                86.4                               0.045
  Brinkman index           591±699 (0--3000)                   795±652 (0--3520)                  0.136
  Hypertension (%)         41.9                                73.8                               0.001
  SBP, mmHg                127±17 (94--168)                    133±15 (98--180)                   0.048
  DBP, mmHg                71±9 (52--91)                       78±11 (57--111)                    0.005
  Diabetes (%)             71.0                                80.6                               0.254
  FBG, mg/dL               119±35 (80--216)                    130±35 (56--261)                   0.123
  HbA1c, (NGSP),%          6.8±1.1 (4.9-8.9)                   7.0±1.1 (5.4-10.7)                 0.292
  HOMA-IR, units           2.0±1.9 (0.47-8.0)                  3.3±2.4 (0.63-14.1)                0.038
  eGFR, mL/min             72.3±16.8 (43.0-103.4)              68.7±18.0 (24.4-110.6)             0.346
  UACR, mg/g creatinine    244.6±869.9 (0.5-3958)              156.5±435.4 (1.0-2880)             0.519
  Dyslipidemia (%)         54.8                                71.8                               0.075
  T-cho, mg/dL             198±38 (137.8-271)                  191±36 (112--335)                  0.349
  LDL-C, mg/dL             117±35 (68--182)                    111±33 (55--259)                   0.337
  TG, mg/dL                87±35 (32--182)                     159±97 (51--681)                   \<0.001
  HDL-C, mg/dL             63±24 (31--157)                     50±12 (56--261)                    \<0.001

Data are mean ± SEM (range), or number of subjects. Abbreviations as in Table [1](#T1){ref-type="table"}. P values \<0.05 were considered statistically significant.

![**Circulating levels of EPA, DHA, AA, EPA/AA ratio, DHA/AA ratio, and (EPA+DHA)/AA ratio in subjects with eVFA \<100 cm**^**2**^**and ≥100cm**^**2**^**.** Data are mean±SEM. Statistical comparisons by the Mann--Whitney U-test or Student's *t*-test. Abbreviations as in Figure [1](#F1){ref-type="fig"}.](1743-7075-10-25-3){#F3}

![**Prevalence of metabolic syndrome and cardiovascular diseases (CAD) in subjects with eVFA \<100 cm**^**2**^**and ≥100cm**^**2**^**.** Data are mean±SEM. Statistical comparisons by the Mann--Whitney U-test or Student's *t*-test. Abbreviations as in Figure [1](#F1){ref-type="fig"}.](1743-7075-10-25-4){#F4}

Discussion
==========

The following were the major findings of the present study: 1) stepwise analysis demonstrated that age and eVFA correlated significantly and independently with serum EPA/AA ratio, and 2) Subjects with eVFA ≥100 cm^2^ had lower serum EPA/AA ratio and were more likely to have metabolic syndrome and history of CAD, compared to those with eVFA \<100 cm^2^.

The preset subjects were males only. Another preliminary studies analyzed the difference of serum EPA/AA ratio in female subjects with eVFA \<100 cm^2^ and ≥100 cm^2^ (n=100, data not shown). There was no significant difference of serum EPA/AA ratio in between female subjects with eVFA \<100 cm^2^ and ≥100 cm^2^ (n=61/39, 0.37±0.27 versus 0.38±0.25, p=0.9236), and the two groups had lower serum EPA/AA levels. These data suggested that Japanese females may have an aversion to fish intake. Further studies including larger number of female subjects with eVFA ≥100 cm^2^ are needed to clarify the correlation between serum EPA/AA and eVFA.

In Japan, the percentage of high-fat food intake from animal sources per total daily calories has been increasing every year, based on the annual reports of the Ministry of Health, Labour and Welfare (<http://www0.nih.go.jp/eiken/chosa/kokumin_eiyou/>). The optimal dietary fat profile includes low intake of both saturated and omega-6 fatty acids and a moderate intake of omega-3 fatty acids \[[@B11]\]. Omega-3 and omega-6 fatty acids are essential because they are not synthesized by the body and must be obtained through diet or supplementation \[[@B12]\]. Omega-6 fatty acids, which are present in most seeds, vegetable oils, and meat, are prothrombotic and proinflammatory \[[@B12]\]. In contrast, omega-3 fatty acids, eicosapentaenoic acid and docosahexaenoic acid, which are present in most fish, such as salmon and tuna, and fish oil, are anti-thrombotic and anti-inflammatory \[[@B12]\]. The present study demonstrated a negative correlation between EPA/AA ratio and visceral fat area (Figure [2](#F2){ref-type="fig"} and Table [3](#T3){ref-type="table"}). Experimental and clinical studies suggest that insulin resistance could explain this negative relationship. Previous studies in diabetic rats demonstrated that long-term intake of EPA prevented insulin resistance, at least in part by improving hypertriacylglycerolemia \[[@B13]\]. Furthermore, low EPA/AA ratio, which is associated with insulin resistance, was also reported in young Japanese adults \[[@B14]\]. Another study demonstrated that the omega-3/omega-6 ratio correlated with HOMA-IR levels in subjects with the metabolic syndrome \[[@B15]\].

Our results demonstrated that subjects with eVFA ≥100 cm^2^ had lower serum EPA/AA ratio, but not serum DHA/AA, and were more likely to have history of CAD, compared to those with eVFA \<100 cm^2^. A low ratio of n-3 to n-6 polyunsaturated fatty acids is associated with cardiovascular events \[[@B4],[@B6],[@B16]-[@B18]\]. However, either study had analyzed the patients with CAD or ischemic stroke, i.e. secondary preventive groups. The present study in lifestyle-related subjects suggests that low EPA/AA ratio may be important in primary prevention of cardiovascular events. Changes in food culture, such as low fish intake and high meat intake, i.e., low EPA/AA ratio, may explain at least in part the worldwide trend of increased prevalence of the metabolic syndrome and atherosclerotic cardiovascular diseases. Intervention with fish oil supplements high in EPA has shown a trend in reduced mortality in CAD patients with substantial reduction in the risk of sudden cardiac death \[[@B19],[@B20]\]. Further intervention trials are needed to address the effect of balanced EPA/AA diet on the incidence of the metabolic syndrome.

In conclusion, the present study showed that low EPA/AA ratio correlated with visceral fat accumulation in male subjects, and subjects with eVFA ≥100 cm^2^ had lower serum EPA/AA ratio and were more likely to have the metabolic syndrome and history of cardiovascular disease, compared to those with eVFA \<100 cm^2^. The balance of EPA/AA by lifestyle modification and medication (such as EPA-based medications) could be useful in reducing the prevalence of the metabolic syndrome and atherosclerosis.

Study limitations
-----------------

The present study has certain limitations. First, this is a cross-sectional study, making it difficult to establish a cause-effect relationship. Second, the results may not be applicable to females or non-Japanese populations. Third, there is bias in single center trials. Fourth, the number of patients may be relatively small. Finally, our study measured abdominal visceral fat area by the bioelectrical impedance method. Measurements of both visceral and subcutaneous fat areas by computed tomography are more accurate.
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